세계의 자가세포 치료 시장 보고서(2025년)

Autologous cell therapy stands as a method within cell therapy where an individual's cells are gathered, processed, and subsequently reintroduced into their own body to address therapeutic needs. It plays a vital role in regenerative medicine, aiming to repair, replace, or rejuvenate damaged tissues or organs.

Within autologous cell therapy, two primary types are prevalent, autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy, a specific facet of this therapy, harnesses stem cells sourced from the patient's own body for therapeutic purposes. These stem cells are derived from various sources such as bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, among others. Their applications span across a wide spectrum of medical areas, including cancer, neurodegenerative disorders, cardiovascular issues, autoimmune conditions, orthopedics, and wound healing. This therapy finds application across multiple sectors including hospitals, clinics, ambulatory centers, academic and research institutions, and other healthcare settings, serving as a versatile approach in addressing various health challenges.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The autologous cell therapy market research report is one of a series of new reports from The Business Research Company that provides autologous cell therapy market statistics, including autologous cell therapy industry global market size, regional shares, competitors with a autologous cell therapy market share, detailed autologous cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. This autologous cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autologous cell therapy market size has grown rapidly in recent years. It will grow from $10.28 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to advancements in regenerative medicine, increased prevalence of chronic diseases, enhanced understanding of cellular biology, patient preference for personalized medicine, clinical success and positive outcomes.

The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $23.22 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to continued growth in regenerative medicine, expanding applications across medical specialties, advancements in cell culture techniques, increasing investment and research initiatives, regulatory support, and standardization. Major trends in the forecast period include the development of automated manufacturing technologies, integration of biomarkers in treatment strategies, the emergence of point-of-care cell processing, expansion beyond hematopoietic stem cells, collaborations, and partnerships in the industry.

The forecast of 17.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. regenerative medicine by increasing the cost of cell processing systems and cryopreservation media sourced from Singapore and Italy, thereby delaying personalized therapies and elevating cancer treatment center costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The burgeoning prevalence of chronic diseases is poised to fuel the expansion of autologous cell therapy. Chronic diseases, persisting for more than a year, necessitate continual medical attention. Autologous cell therapy, leveraging an individual's cultivated and amplified cells reintroduced into the donor, holds promise in managing and treating such conditions. According to the National Library of Medicine's January 2023 report, the US is projected to witness 142.66 million people aged 50 and above with at least one chronic condition by 2050. Hence, the heightened prevalence of chronic diseases propels the growth of the autologous cell therapy market.

The increasing aging population is expected to drive the growth of the autologous cell therapy market in the coming years. An aging population refers to the rise in median age within a population due to declining fertility rates and longer life expectancy. Autologous cell therapies can benefit this demographic by providing targeted and personalized treatment options. For instance, in July 2024, the Office of National Statistics, a UK-based producer of official statistics, reported that in 2022, approximately 12.7 million people in the UK were aged 65 and over, representing 19% of the total population. Projections indicate that by 2072, this figure could rise to 22.1 million, making up 27% of the population. Consequently, the growing aging population is fueling the expansion of the autologous cell therapy market.

Technological advancements emerge as a prominent trend shaping the autologous cell therapy market. Market leaders are automating the process to enhance efficiency and ensure sustainability. Lonza, for instance, unveiled the Cocoon Platform in April 2022, a cutting-edge technology streamlining personalized cell and gene therapy manufacturing. This platform, driven by an automated closed system, minimizes contamination risk, upholds manufacturing sterility, substantially bolsters quality, reduces labor and material expenses, and facilitates the scalable production of autologous T-cell products.

Major players in the autologous cell therapy realm are forging strategic partnerships and collaborations to fortify their market positions. Strategic partnerships, fostering collaborative endeavors between multiple entities, aim to achieve specific business objectives. Notably, in March 2022, Novartis inked an initial agreement with Carisma Therapeutics, aiming to manufacture HER 2 targeted CAR-M cell therapy. The collaboration involves transferring Carisma Therapeutics' manufacturing process to Novartis' Cell Therapy Site in the US, scheduling clinical manufacturing to commence in 2023, focusing on treating solid tumors in initial trials.

In October 2023, Clade Therapeutics, a US-based cell therapy company, successfully acquired Gadeta B.V. for an undisclosed sum. This strategic acquisition significantly enriches Clade's repertoire by incorporating innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies tailored for cancer patients into its existing portfolio. Gadeta B.V., based in the Netherlands, specializes in the development of cell therapies.

Major companies operating in the autologous cell therapy market include Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation

North America was the largest region in the autologous cell therapy market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autologous Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autologous cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autologous cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The autologous cell therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Autologous Stem Cell Therapy; Autologous Cellular Immunotherapies
• 2) By Source: Bone Marrow; Epidermis; Mesenchymal Stem Cells; Hematopoietic Stem Cells; Chondrocytes; Other Sources
• 3) By Application: Cancer; Neurodegenerative Disorders; Cardiovascular Disorders; Autoimmune Disorders; Orthopedics; Wound Healing; Other Applications
• 4) By End User: Hospitals And Clinics; Ambulatory Centers; Academics And Research; Other End-Users
• Subsegments:
• 1) By Autologous Stem Cell Therapy: Hematopoietic Stem Cell Transplantation; Mesenchymal Stem Cell Therapy; Adipose-Derived Stem Cell Therapy
• 2) By Autologous Cellular Immunotherapies: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Tumor-Infiltrating Lymphocyte (TIL) Therapy; Dendritic Cell Therapy
• Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Vericel Corporation; Holostem Terapie Avanzate S.r.l.; Pharmicell Co. Ltd.; Opexa Therapeutics Inc.; Tego Science AB; Brainstorm Cell Therapeutics Inc.; Caladrius Biosciences Inc.; Lineage Cell Therapeutics Inc.; Castle Creek Biosciences Inc.; Gilead Sciences Inc.; Johnson & Johnson; CORESTEM Inc.; Dendreon Pharmaceuticals LLC; Medipost Co. Ltd.; PharmaJet Inc.; Bioject Medical Technologies Inc.; Medical International Technology Inc.; INJEX Pharma AG; Lonza Group Ltd.; Corning Incorporated; Takeda Pharmaceutical Company Limited; CSL Limited; AstraZeneca plc; Moderna Inc.; Sinovac Biotech Ltd.; Valneva SE; Bavarian Nordic A/S; Dynavax Technologies Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autologous Cell Therapy Market Characteristics

3. Autologous Cell Therapy Market Trends And Strategies

4. Autologous Cell Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Autologous Cell Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autologous Cell Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autologous Cell Therapy Market Growth Rate Analysis
• 5.4. Global Autologous Cell Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autologous Cell Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autologous Cell Therapy Total Addressable Market (TAM)

6. Autologous Cell Therapy Market Segmentation

• 6.1. Global Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Therapy
• Autologous Cellular Immunotherapies
• 6.2. Global Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Chondrocytes
• Other Sources
• 6.3. Global Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Other Applications
• 6.4. Global Autologous Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Centers
• Academics And Research
• Other End-Users
• 6.5. Global Autologous Cell Therapy Market, Sub-Segmentation Of Autologous Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation
• Mesenchymal Stem Cell Therapy
• Adipose-Derived Stem Cell Therapy
• 6.6. Global Autologous Cell Therapy Market, Sub-Segmentation Of Autologous Cellular Immunotherapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Antigen Receptor (CAR) T-Cell Therapy
• Tumor-Infiltrating Lymphocyte (TIL) Therapy
• Dendritic Cell Therapy

7. Autologous Cell Therapy Market Regional And Country Analysis

• 7.1. Global Autologous Cell Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autologous Cell Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autologous Cell Therapy Market

• 8.1. Asia-Pacific Autologous Cell Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autologous Cell Therapy Market

• 9.1. China Autologous Cell Therapy Market Overview
• 9.2. China Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autologous Cell Therapy Market

• 10.1. India Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autologous Cell Therapy Market

• 11.1. Japan Autologous Cell Therapy Market Overview
• 11.2. Japan Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autologous Cell Therapy Market

• 12.1. Australia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autologous Cell Therapy Market

• 13.1. Indonesia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autologous Cell Therapy Market

• 14.1. South Korea Autologous Cell Therapy Market Overview
• 14.2. South Korea Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autologous Cell Therapy Market

• 15.1. Western Europe Autologous Cell Therapy Market Overview
• 15.2. Western Europe Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autologous Cell Therapy Market

• 16.1. UK Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autologous Cell Therapy Market

• 17.1. Germany Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autologous Cell Therapy Market

• 18.1. France Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autologous Cell Therapy Market

• 19.1. Italy Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autologous Cell Therapy Market

• 20.1. Spain Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autologous Cell Therapy Market

• 21.1. Eastern Europe Autologous Cell Therapy Market Overview
• 21.2. Eastern Europe Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autologous Cell Therapy Market

• 22.1. Russia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autologous Cell Therapy Market

• 23.1. North America Autologous Cell Therapy Market Overview
• 23.2. North America Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autologous Cell Therapy Market

• 24.1. USA Autologous Cell Therapy Market Overview
• 24.2. USA Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autologous Cell Therapy Market

• 25.1. Canada Autologous Cell Therapy Market Overview
• 25.2. Canada Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autologous Cell Therapy Market

• 26.1. South America Autologous Cell Therapy Market Overview
• 26.2. South America Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autologous Cell Therapy Market

• 27.1. Brazil Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autologous Cell Therapy Market

• 28.1. Middle East Autologous Cell Therapy Market Overview
• 28.2. Middle East Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autologous Cell Therapy Market

• 29.1. Africa Autologous Cell Therapy Market Overview
• 29.2. Africa Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autologous Cell Therapy Market Competitive Landscape And Company Profiles

• 30.1. Autologous Cell Therapy Market Competitive Landscape
• 30.2. Autologous Cell Therapy Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Vericel Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Holostem Terapie Avanzate S.r.l. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pharmicell Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Autologous Cell Therapy Market Other Major And Innovative Companies

• 31.1. Opexa Therapeutics Inc.
• 31.2. Tego Science AB
• 31.3. Brainstorm Cell Therapeutics Inc.
• 31.4. Caladrius Biosciences Inc.
• 31.5. Lineage Cell Therapeutics Inc.
• 31.6. Castle Creek Biosciences Inc.
• 31.7. Gilead Sciences Inc.
• 31.8. Johnson & Johnson
• 31.9. CORESTEM Inc.
• 31.10. Dendreon Pharmaceuticals LLC
• 31.11. Medipost Co. Ltd.
• 31.12. PharmaJet Inc.
• 31.13. Bioject Medical Technologies Inc.
• 31.14. Medical International Technology Inc.
• 31.15. INJEX Pharma AG

32. Global Autologous Cell Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autologous Cell Therapy Market

34. Recent Developments In The Autologous Cell Therapy Market

35. Autologous Cell Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Autologous Cell Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autologous Cell Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autologous Cell Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer